Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT06798701
Status
Recruiting
Apply to this trial

Conditions

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Best Practice — OTHER
    Undergo standard care
  • Interview — OTHER
    Ancillary studies
  • Survey Administration — OTHER
    Ancillary studies
  • Virtual Reality — PROCEDURE
    Use VR device

Study Details

This clinical trial compares the use of virtual reality to standard care for improving symptom management in patients undergoing hematopoietic stem cell transplantation (HSCT). Significant symptoms experienced by hospitalized HSCT patients include, but are not limited to, depression, tiredness, anxiety, drowsiness, lack of appetite, pain, and overall decreased quality of life and well-being. Virtual reality (VR) as an intervention can provide these patients with a much-needed escape from their reality and has proven results in clinical settings as a distraction therapy. VR technology targets the patient's auditory, visual, and physical contact/touch senses, and has been evidenced to improve depression, fatigue, anxiety, appetite, and pain. Virtual reality may improve symptom management in patients undergoing HSCT.

Key Dates

Start date
Mar 14, 2025
Status verified
Apr 2026
Primary completion
Jun 14, 2026
Completion
Jun 14, 2026

Study Design

Enrollment
28 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Arm I (VR use)
    Patients use the VR device to participate in applications related to relaxation such as mediation, art and nature, for up to 15 minutes, daily, while inpatient for standard of care HSCT.
  • Active Comparator: Arm II (Standard care)
    Patients undergo standard care for the HSCT.

Primary Outcome Measure

Difference in the trajectories of the mean Edmonston Symptom Assessment System Revised (ESAS-r) composite scores [ Time Frame: Length of hospital stay up to 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263
Heather Huizinga
[email protected]
716-845-5482
Heather Huizinga (PRINCIPAL_INVESTIGATOR)

Find similar trials in Buffalo, NY

By research site
Roswell Park Cancer Institute· Buffalo, NY

Related Studies